Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, United States; Department of Neurology, Harvard Medical School, Boston, MA, United States; Massachusetts General Hospital Biostatistics Center, Boston, MA, United States; Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States.
Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States.
Mult Scler Relat Disord. 2023 Nov;79:105003. doi: 10.1016/j.msard.2023.105003. Epub 2023 Sep 15.
Patient reported outcome measures (PROs) are considered promising tools for use in clinical settings to measure the impact of disease on physical, mental and social well-being from the patient's perspective. The Patient Reported Outcome Measurement Information System Scale v1.1-Global Health (PROMIS-10) is a measure that is well-suited to clinical practice, but the relationships between this measure and longer PRO measures used in multiple sclerosis (MS) research are unknown.
Subjects enrolled in SysteMS: A Systems Biology Study of Clinical, Radiological, and Molecular Markers in Subjects with MS at the Brigham and Women's Hospital were eligible to contribute to the study. 349 subjects completed three PRO measures at study entry: PROMIS-10, Medical Outcomes Study Short-Form 36 (SF-36), and Quality of Life in Neurological Disorders (Neuro-QoL™). All questions and global scores from PROMIS-10 were correlated with all domain and summary component scores for SF-36 and all domain scores for Neuro-QoL using Pearson's correlation coefficient. Further, the global scores from PROMIS-10 were correlated with the expanded disability status scale (EDSS) and compared between disease categories (relapsing vs progressive MS).
Strong correlations were observed between PROMIS-10 questions and SF-36 domains aimed at measuring the same construct. Further, the PROMIS-10 Global Physical Health score was correlated with the Physical Component Score from the SF-36 (r = 0.798), and the PROMIS Global Mental Health score was correlated with the Mental Component Score from the SF-36 (r = 0.726). Strong correlations between PROMIS-10 questions and two Neuro-QoL domains (fatigue and lower extremity function) were observed, but other Neuro-QoL domains were not strongly correlated with PROMIS-10 questions. PROMIS-10 Global Physical Health had stronger relationship to EDSS and disease category compared to the Global Mental Health.
PROMIS-10 questions and global scores are highly correlated with the corresponding domains of SF-36 in PwMS. Neuro-QoL provides different information regarding HRQOL since different domains are being measured.
患者报告的结局测量（PROs）被认为是在临床环境中用于从患者角度衡量疾病对身体、心理和社会健康影响的有前途的工具。患者报告结局测量信息系统量表 v1.1-全球健康（PROMIS-10）是一种非常适合临床实践的测量方法，但该测量方法与多发性硬化症（MS）研究中使用的更长的 PRO 测量方法之间的关系尚不清楚。
在布里格姆妇女医院进行的 SysteMS：MS 患者临床、放射学和分子标志物系统生物学研究中入组的受试者有资格参与该研究。349 名受试者在研究入组时完成了三种 PRO 测量：PROMIS-10、医疗结局研究短式 36 项（SF-36）和神经疾病生活质量（Neuro-QoL™）。使用 Pearson 相关系数将 PROMIS-10 的所有问题和全球评分与 SF-36 的所有领域和综合成分评分以及 Neuro-QoL 的所有领域评分相关联。此外，还将 PROMIS-10 的全球评分与扩展残疾状况量表（EDSS）相关联，并在疾病类别（复发型与进展型 MS）之间进行比较。
观察到 PROMIS-10 问题与旨在测量相同结构的 SF-36 领域之间存在很强的相关性。此外，PROMIS-10 全球生理健康评分与 SF-36 的生理成分评分相关（r=0.798），PROMIS 全球心理健康评分与 SF-36 的心理成分评分相关（r=0.726）。观察到 PROMIS-10 问题与 Neuro-QoL 的两个领域（疲劳和下肢功能）之间存在很强的相关性，但其他 Neuro-QoL 领域与 PROMIS-10 问题没有很强的相关性。与全球心理健康相比，PROMIS-10 全球生理健康与 EDSS 和疾病类别具有更强的关系。
在多发性硬化症患者中，PROMIS-10 问题和全球评分与 SF-36 的相应领域高度相关。Neuro-QoL 提供了不同的 HRQOL 信息，因为正在测量不同的领域。
